Drug Approval | June 23, 2026
Teva submits FDA application for experimental Tourette syndrome treatment ecopipam
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
New AMF Series combines industry-leading 1000:1 turndown capability, predictive diagnostics, and digital connectivity in a footprint no larger than a standard Post-it Note pad
Healthcare speed-scaling platform offers clinical validation, regulatory support, mentorship, and investor access to startups working across preventive health, oncology, genomics, diagnostics, and digital health
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
